January 4, 2018 5:48pm
As I stated, “we … saw two (2) positives closes with highs but decliners are edging up from 7 to 15 and a major snow storm could tilt the markets!”
The IBB was down -0.82% after being up +1.04% over two (2) sessions with the NASDAQ hits new record
Pre-open indications: 2 hits, 4 miss
Out and about: The Biostage (BSTG +$0.46) chronicles …
Thursday’s results have implications to Friday’s sector activity as a daily report may say little or a lot and it serves as insurance that all indications are being examined and evaluated!
Henry’omics:
From the pre-open’s newsletter, “ the sector … re-upsides. The first week of the year has already shown 2018 to be beneficial for “our” universe yet volume is still on the low side as we meander through the maze of fundamentals and facts – visible or obscured.”
As I stated, “And we have seen two (2) positives closes with highs but decliners are edging up from 7 to 15 and a major snow storm could tilt the markets!”
What's driving the sector swings, it cetainly is NOT sentiment - speculation in its purest form!
Momentum was the single-biggest factor driving prices in 2017 and that remains the case so far these newest days.
Valuations are stretched, no question, based on last year's values and I feel we SHOULD beconcerned about them at this point in time especially with JP Morgan's healthcare conference next week along with the add-on mini-conferences for those excluded.
The advance/decline line scenario of 40 SCGT & RT covered companies:
· The open was negative with an A/DL of 13/25 and 2 flat ;
· The mid-day was negative with an A/DL of 16/21 and 3 flat;
· The close was positive with an A/DL of 21/19 and 0 flat;
MY working trend lines or indications:
… The greatest volume to the downside: XON, ONCE, IMUC, FCSC and RENE.L
… Upside volume was weighted to: NWBO, ADVM, ONVO, MDXG and AST
… Biggest $ downside: ONCE (-$3.92), BLUE (-$2.65), XON (-$1.19), STML (-$0.80) and RGNX (-$0.60)
… Largest $ upside: AXGN (+$0.50), FATE (+0.49), SGMO (+0.45), ADRO (+0.40) and AST (+$0.30)
… Flat: NONE
Pre-open indications:
- Adverum (ADVM) closed up +$0.10 – miss;
- BioLife (BLFS) closed up +$0.07 – hit;
- Biostage (BSTGD) closed up +$0.46 – miss – be wary;
- Cellectis SA (CLLS) closed up +0.20 – miss;
- Intrexon (XON) closed down -$1.19 – hit;
- Sangamo Therapeutics (SGMO) closed up +$0.45 – miss;
Out and about:
BSTGD closes $4.2 M private placement … https://finance.yahoo.com/news/biostage-closes-4-2-million-140000425.html
This management team WIPED OUT 40 M of shareholders holdings and investment!
Opened at $1.75 (previous closed $1.75) then advanced +$0.46 or +26.29% to close up in a day’s range of $1.65 to $2.40 with 42,365 shares traded following the projected $1.32 post the 1-to-20 reverse split – a $4 M in-flow just followed a $30 M investment loss incurring a $47 M deficit!
Who and what’s “playing” the stock – day traders.
- NO scientists, a CEO, CFO and 2 accountants don’t make a company who couldn’t pay their rent or communicate their issues to past “fleeced” shareholders …
I am NOT “eating” my negative declarations, my OPINION is still “FRAUD” and “COVER UP of MISDEEDS “by this management team!
- It ain't over, more than many investors are agitating ... it will continue to spill over!!
Remember, day traders come and go as fast as a push on the SELL button with loyalty to NOTHING!
- 20 M shares DISCARDED along with the shareholders money! SHAME on you McGorry and McNaughton!
Daily analytics:
U.S. stock-market indexes closed at all-time highs on Thursday, while the Dow topped the 25,000 milestone for the first time. While 25,000 is seen as a psychologically significant level, it otherwise holds no fundamental or technical importance.
· The Dow rose 152.45 points, or 0.6%, to finish at 25,075.13.
· The S&P 500 rose 10.93 points, or 0.4%, to close at 2,723.99.
· The NASDAQ gained 12.38 points, or 0.2%, finishing at 7,077.91.
The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, Thursday traded at 9.22, up +0.77% …
- Wednesday traded at 9.15, down -6.35% after Tuesday traded at 9.77, down -11.50%, Monday was New Year’s day, Friday traded at 10.79, up +5.99% after last Thursday traded at 10.28, down -2.77% …
Welcome to another day of the sector’s roller coaster …
… The iShares Russell 2000 (IWM) indicated:
· Thursday was up +0.24%
· Wednesday was up +0.12%
· Tuesday was up +0.92%
· Monday was New Year’s Day
· Friday was down -0.80%
· Last Thursday +0.40%
… The iShares NASDAQ Biotechnology (IBB) indicated:
· Thursday was down -0.82%
· Wednesday was up +1.41%
· Tuesday was up +2.41%
· Monday was New Year’s Day
· Friday was down -0.95%
· Last Thursday was up +0.19%
The count - decliners versus gainers:
……. look at the differences in decliners:
· Thursday’s decliners ranged from -0.70% <PSTI -$0.01> to -8.45% <XON -$1.19> in 19 equities;
· Wednesday’s decliners ranged from -0.62% <MDXG -$0.08> to -5.42% <CUR -$0.11> in 15 equities;
· Tuesday’s decliners ranged from -0.63% <CAPR -$0.01> to -% <BCLI -$0.27> in 7 equities;
· Monday was a holiday
· Friday’s decliners ranged from -0.35% <FCSC -$0.00> to -6.52% <AST -$0.15> in 25 equities;
· Last Thursday’s decliners ranged from -0.11% <BLUE -$0.20> to -8.28% <FATE -$0.55> in 20 equities;
Versus
… Look at the percentage’s (%) and spreads …
· Thursday’s gainers ranged from +0.45% <QURE +$0.09> to +13.95% <AST +$0.30> in 21 equities;
· Wednesday’s gainers ranged from +0.32% <KOOL +$0.01> to +17.81% <ADVM +$0.65> in 23 equities
· Tuesday’s gainers ranged from +0.32% <STML +$0.05> to +18.02% <CUR +$0.31> in 31 equities
· Monday was a holiday
· Friday’s gainers ranged from +0.17% <MESO +$0.01> to +29.37% <BCLI +$0.89> in 14 equities
· Last Thursday’s gainers ranged from +0.53% <AXGN +$0.15> to +5.96% <ISCO +$0.09> in 15 equities
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.